Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/FLNA/Filing changes

FLNA — what changed in the latest 10-Q

A section-by-section comparison of FLNA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.

Comparing 10-Q · 2026-07-29 vs the prior 10-Q · 2026-05-07

SectionOutcomeAddedRemovedMinorUnchanged
MD&AText added/removed+6−4~24105
Market risk (Item 3)No paragraph-level changes0001
Controls & proceduresText added/removed00~21
Legal proceedingsNo paragraph-level changes0001
Risk factorsNo material changes reported (points to the 10-K)————
Other informationText added/removed00~10

Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.

Representative excerpts

Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.

MD&A

Text added vs the prior filing · source: 10-Q · 2026-07-29

  • Research and development expenses were $7.8 million and $18.8 million during the six months ended June 30, 2026 and 2025, respectively. This 58% decrease was due primarily to the phase out of the Alzheimer's disease development program, which was completed in the second quarter of 2025.
  • General and administrative expenses were $12.7 million and $51.2 million during the six months ended June 30, 2026 and 2025, respectively. The 75% decrease was due primarily to a $31.3 million securities litigation loss contingency and other legal loss contingencies of $3.0 million recorded in the f…
  • Interest income was $1.5 million and $2.5 million during the six months ended June 30, 2026 and 2025, respectively. The decrease in interest income was due primarily to lower interest rates and cash balances in 2026 compared to 2025.
  • We expect interest income to decrease in future quarters as we continue to utilize cash in our operations.
  • We record the activities related to leasing office space to third parties in buildings we own as other income (loss), net, as leasing is not core to the Company’s operations. Other income (loss), net, was $43,000 and $(46,000) during the three months ended June 30, 2026 and 2025, respectively.

Text removed vs the prior filing · source: 10-Q · 2026-05-07

  • The Company is working expeditiously to address the items identified in the letter. However, as announced on December 18, 2025, the Company no longer expects to initiate a proof-of-concept clinical trial for simufilam in TSC-related epilepsy in the first half of 2026. The updated timing for initiati…
  • We expect interest income to decrease in future quarters as we utilize cash in our operations and realize the impact of a lower interest rate environment.
  • We record the activities related to leasing office space to third parties in buildings we own as other income (loss), net, as leasing is not core to the Company’s operations. Other income (loss), net, was $48,000 and $(82,000) during the three months ended March 31, 2026 and 2025, respectively.
  • We recorded other income in the three months ended March 31, 2026 due to improved occupancy rates in 2026 compared to the prior year period. We expect to record modest net income on leasing activities in 2026 due to improved occupancy.

How to read Risk Factors (Item 1A) in a 10-Q

A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:

  • Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
  • Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
  • Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.

This describes the filing structure only — it is never a judgement on whether risk went up or down.

Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice

More on FLNA

FLNA overviewFLNA quant ratingFLNA fair value (DCF)FLNA vs peersFLNA revenue historyFLNA AI deep research